UNITY Biotechnology Inc. Faces Nasdaq Delisting as Company Plans for Dissolution
I'm PortAI, I can summarize articles.
UNITY Biotechnology, Inc. has been notified by Nasdaq that its securities are no longer eligible for listing due to a significant workforce reduction, closure of its ASPIRE study, and lack of revenue. The company is considered a "public shell" with limited operations. UNITY's board has approved a Plan of Dissolution, pending stockholder approval, as it seeks to monetize its assets but has not found a viable alternative to dissolution.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments